HIV Prevention Research & Development Investments
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group (“Working Group”) documents research and development spending for the calendar year 2021 and analyzes funding trends spanning twenty years.
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
The Working Group’s 2021 analysis builds on the US$20 billion in funding tracked between 2000 and 2020 and underscores the importance of continued innovation in HIV prevention to bring a lasting end to the HIV/AIDS pandemic.
The biomedical HIV prevention options tracked include preventive AIDS vaccines, microbicides, prevention of vertical transmission (PMTCT), pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC) and female condoms.